IPP Bureau

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

By IPP Bureau - March 14, 2026

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days

Almirall opens Shanghai hub to power dermatology innovation and China partnerships
Almirall opens Shanghai hub to power dermatology innovation and China partnerships

By IPP Bureau - March 14, 2026

The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development

Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases
Meiji Seika Pharma launches first-in-human trial of Novel PD-1 agonist for autoimmune diseases

By IPP Bureau - March 14, 2026

The early-stage study will test the drug’s safety, tolerability and biological effects in humans

GelMEDIX partners with Catalent to advance vision-restoring cell therapies
GelMEDIX partners with Catalent to advance vision-restoring cell therapies

By IPP Bureau - March 14, 2026

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing

Veristat expands global trial & regulatory services as Chinese drugmakers push overseas
Veristat expands global trial & regulatory services as Chinese drugmakers push overseas

By IPP Bureau - March 14, 2026

The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals

Biogen unveils promising new data for Salanersen in kids with SMA
Biogen unveils promising new data for Salanersen in kids with SMA

By IPP Bureau - March 14, 2026

Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains

Zydus receives USFDA approval for cevimeline hydrochloride capsules
Zydus receives USFDA approval for cevimeline hydrochloride capsules

By IPP Bureau - March 14, 2026

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.

Caplin Steriles gets USFDA approval for potassium phosphates injection
Caplin Steriles gets USFDA approval for potassium phosphates injection

By IPP Bureau - March 14, 2026

Single-use gloves misused across India, raising health risks
Single-use gloves misused across India, raising health risks

By IPP Bureau - March 14, 2026

One task, one interaction, one pair, experts advocate

Aster DM bags overwhelming shareholder backing for merger with Quality Care
Aster DM bags overwhelming shareholder backing for merger with Quality Care

By IPP Bureau - March 14, 2026

The endorsement follows overwhelming support for the share swap preceding the merger,

Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing
Natural Biogenex joins forces with Fermbox Bio to boost fermentation-based biomanufacturing

By IPP Bureau - March 14, 2026

The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand

Wanbury bags key Brazil nod, eyes market expansion
Wanbury bags key Brazil nod, eyes market expansion

By IPP Bureau - March 14, 2026

Pharmaceutical manufacturer Wanbury Limited (WL) has strengthened its position in the Brazilian market after securing regulatory approval for Sertraline Form II from Brazil’s health regulator, ANVISA

Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO
Middle East conflict pushes health systems to brink as casualties, displacement surge: WHO

By IPP Bureau - March 14, 2026

The conflict is also triggering a widening public health emergency

Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore
Jubilant Ingrevia acquires Remidex Pharma for Rs 16.5 crore

By IPP Bureau - March 14, 2026

Remidex manufactures micronutrient premixes and nutraceuticals,

APL Healthcare’s Unit-IV classified as VAI by the USFDA
APL Healthcare’s Unit-IV classified as VAI by the USFDA

By IPP Bureau - March 14, 2026

This inspection is now closed

Latest Stories

Interviews

Packaging